Development of a stability-indicating HPLC method and a dissolution test for rivaroxaban dosage forms

Souri, Effat; Mottaghi, Siavash; Zargarpoor, Mohammad; Ahmadkhaniha, Reza; Jalalizadeh, Hassan

doi:10.1556/1326.2016.28.3.05

Cited by 9 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The optimized method employs a RP column, Phenomenex Kinetex EVO C18 (250×4.6 mm; 5μ), a mobile phase of triethylammonium phosphate buffer (pH 2.0):methanol: acetonitrile in the proportion of 30:30:40 v/v, flow rate of 0.6 ml/min and a detection wavelength of 254 nm using a UV detector. Souri et al [27] studied a stability-indicating HPLC method for the quantitative determination of rivaroxaban in pharmaceutical dosage forms. Rivaroxaban was subjected to acidic, basic, oxidative, photolytic, and thermal conditions for forced stress degradation studies.…”

Section: Chromatographymentioning

confidence: 99%

Quantification of Anticoagulants Dabigatran, Rivaroxaban, and Prasugrel by Chromatographic and Spectrometric Techniques – Review

Jayakumari

2019

Asian J Pharm Clin Res

View full text Add to dashboard Cite

A review is presented on different analytical techniques used for quantitative analysis of selected anticoagulants dabigatran, rivaroxaban, and prasugrel. Efforts have been made to collate all the relevant references to the extent possible. The review discusses the advantages and disadvantages of the cited analytical techniques, which will help to give insights into the methods used for estimation of selected anticoagulants such as dabigatran, rivaroxaban, and prasugrel, from clinical isolates, and its dosage forms. The review highlights the basic as well as advanced techniques performed for estimating dabigatran, rivaroxaban, and prasugrel. The techniques illustrated here have been demonstrated to be useful for quantitative determination of selected anticoagulants and may find application in analyzing other related properties.

show abstract

Section: Chromatographymentioning

confidence: 99%

Quantification of Anticoagulants Dabigatran, Rivaroxaban, and Prasugrel by Chromatographic and Spectrometric Techniques – Review

Jayakumari

2019

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

A review on: analysis of the first oral, direct factor Xa inhibitor; Rivaroxaban

Hosny

2020

Microchemical Journal

View full text Add to dashboard Cite

A sustainable and green HPLC-PDA technique for the simultaneous estimation of Post-COVID-19 syndrome co-administered drugs with greenness and whiteness assessment

Medhat,

Fouad,

Monir

et al. 2024

Sci Rep

View full text Add to dashboard Cite

COVID-19 has been a growing global concern in the past four years. Several syndromes associated with this multi-organ viral infection have been observed since the outbreak. According to estimates, 10–15% of people with SARS-CoV- infection may have post-COVID-19 syndrome. Even months after infection, common residual signs and symptoms include myalgia, exhaustion, shortness of breath, rapid heartbeat, stroke, and memory and cognitive impairment which can negatively affect survivors’ quality of life and may consequently lead to their death. Therefore, it is necessary to think about potential therapy options for dealing with both short and long-term impacts. Paracetamol (a common analgesic and antipyretic) and Dexketoprofen Trometamol (a non-steroidal anti-inflammatory drug) are used together to relieve post-COVID symptoms like myalgia (muscle pain) and headache. Additionally, to prevent thrombotic events, Rivaroxaban is recommended for 35 days following discharge. Thus an eco-friendly HPLC-DAD technique was developed for simultaneous quantification of Paracetamol, Dexketoprofen Trometamol, and Rivaroxaban which are co-administered for treatment of post-COVID-19 syndrome. The suggested method was found to be linear in the concentration ranges of 3.00–45.00 µg/mL, 0.5–50.00 µg/mL, and 0.15–20.00 µg/mL, and a limit of detection down to 0.531 µg/mL, 0.095 µg/mL and 0.047 µg/mL for Paracetamol, Dexketoprofen Trometamol and Rivaroxaban, respectively. This method was effectively used to quantify the studied drugs in their bulk powder and spiked human plasma with high percentage recoveries (96.55–99.46%). The suggested approach was validated per International Conference on Harmonization (ICH) requirements and found to be within the acceptable ranges. The method was developed using Green Analytical Chemistry (GAC) principles, with the solvents used and run time having a significant effect on the method’s greenness. “Non-toxic” ethanol served as the organic modifier in the mobile phase, moreover, the total run time was 12 min making it suitable for the routine analysis of the mentioned drugs in plasma samples. To get a full image of the method’s greenness profile; two most recent greenness assessment tools, the Green Analytical Procedure Index (GAPI), and the Analytical GREEnness metric (AGREE), were employed, with White Analytical Chemistry (WAC) principles proving its environmental safety.

show abstract

Development of a stability-indicating HPLC method and a dissolution test for rivaroxaban dosage forms

Cited by 9 publications

References 7 publications

Quantification of Anticoagulants Dabigatran, Rivaroxaban, and Prasugrel by Chromatographic and Spectrometric Techniques – Review

Quantification of Anticoagulants Dabigatran, Rivaroxaban, and Prasugrel by Chromatographic and Spectrometric Techniques – Review

A review on: analysis of the first oral, direct factor Xa inhibitor; Rivaroxaban

A sustainable and green HPLC-PDA technique for the simultaneous estimation of Post-COVID-19 syndrome co-administered drugs with greenness and whiteness assessment

Contact Info

Product

Resources

About